作者
Hossein-Ardeschir Ghofrani, Andrea M D'Armini, Friedrich Grimminger, Marius M Hoeper, Pavel Jansa, Nick H Kim, Eckhard Mayer, Gerald Simonneau, Martin R Wilkins, Arno Fritsch, Dieter Neuser, Gerrit Weimann, Chen Wang
发表日期
2013/7/25
期刊
New England Journal of Medicine
卷号
369
期号
4
页码范围
319-329
出版商
Massachusetts Medical Society
简介
Background
Riociguat, a member of a new class of compounds (soluble guanylate cyclase stimulators), has been shown in previous clinical studies to be beneficial in the treatment of chronic thromboembolic pulmonary hypertension.
Methods
In this phase 3, multicenter, randomized, double-blind, placebo-controlled study, we randomly assigned 261 patients with inoperable chronic thromboembolic pulmonary hypertension or persistent or recurrent pulmonary hypertension after pulmonary endarterectomy to receive placebo or riociguat. The primary end point was the change from baseline to the end of week 16 in the distance walked in 6 minutes. Secondary end points included changes from baseline in pulmonary vascular resistance, N-terminal pro–brain natriuretic peptide (NT-proBNP) level, World Health Organization (WHO) functional class, time to clinical worsening, Borg dyspnea score, quality-of-life …
学术搜索中的文章
HA Ghofrani, AM D'Armini, F Grimminger, MM Hoeper… - New England Journal of Medicine, 2013